Welcome to our dedicated page for Humacyte news (Ticker: HUMA), a resource for investors and traders seeking the latest updates and insights on Humacyte stock.
Humacyte, Inc. reports commercial, clinical and regulatory developments for its bioengineered human tissue platform. The company’s first FDA-approved product, Symvess, is an acellular tissue engineered vessel indicated for treatment of extremity vascular trauma, while other ATEV applications remain part of its broader regenerative medicine pipeline.
Recurring updates include Symvess commercialization, hospital access and distribution arrangements, international regulatory submissions, and clinical work in arteriovenous access for hemodialysis patients. Humacyte also reports quarterly financial results, business-development activity, financing actions and leadership changes tied to its transition from platform development to commercial-stage biotechnology operations.
Humacyte (Nasdaq: HUMA) announced that one‑year results from its V007 Phase 3 trial of the acellular tissue engineered vessel (ATEV) for arteriovenous (AV) access in hemodialysis patients have been published in The Lancet Digital Health. The multicenter randomized trial compared ATEV with autogenous arteriovenous fistula (AVF) and, according to Humacyte, showed superiority of ATEV for hemodialysis vascular access after one year, especially in all women and in men with obesity and diabetes, who often experience higher AVF failure rates.
The publication adds peer‑reviewed validation to V007 data and complements interim Phase 3 V012 results, in which ATEV outperformed standard of care in women on dialysis and met the primary superiority endpoint. Based on V012, Humacyte plans to submit a supplemental Biologics License Application in the second half of 2026 to expand the Symvess® label to a second indication in AV access. Outside the FDA‑approved extremity vascular trauma indication, ATEV remains investigational and is not approved for sale for other uses.
Humacyte (Nasdaq: HUMA) announced that board-certified vascular and endovascular surgeon Jeromy Brink, MD, has performed the first post‑BLA‑approval Symvess implants in Arizona at Banner University Medical Center in Phoenix, completing four procedures within two weeks of gaining access to the product.
Symvess, an FDA‑approved acellular tissue engineered vessel, is indicated as a vascular conduit for adults with extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss and an autologous vein graft is not feasible. The off‑the‑shelf vessel is available on demand in the operating room. Humacyte highlights important safety information, including a boxed warning for graft failure, risks of graft rupture, anastomotic failure, thrombosis, and potential transmission of infectious diseases. Uses outside the approved extremity vascular trauma indication remain investigational.
Humacyte (Nasdaq:HUMA) reported second quarter 2026 results and a broad business update, highlighted by breakthrough interim data from the V012 Phase 3 trial of its acellular tissue engineered vessel (ATEV) in female dialysis patients, where ATEV was observed to outperform AV fistula and significantly reduce catheter use and infections. Based on V012 plus prior V007 results, the company plans to file a supplemental Biologics License Application for dialysis access with the FDA in the second half of 2026.
Humacyte also reported FDA acceptance of its IND for a first‑in‑human Phase 2a CABG study using its coronary tissue engineered vessel (CTEV), expanding its cardiovascular pipeline. Second quarter 2026 Symvess® sales rose to $0.4 million from $0.1 million a year earlier, and first‑half 2026 sales reached $0.9 million versus $0.2 million. The company completed a $57.5 million public equity offering, implemented cost reductions expected to yield about $14.3 million in 2026 savings, and ended June 30, 2026 with $80.3 million in cash, cash equivalents and restricted cash, despite reporting a quarterly net loss of $36.8 million.
Humacyte (Nasdaq: HUMA) will release financial results for the three and six months ended June 30, 2026 on Wednesday, August 12, 2026, followed by a webcast and conference call at 8:00 a.m. Eastern Time to provide corporate and financial updates.
Humacyte develops universally implantable, bioengineered human tissues. Its Biologics License Application for Symvess, an acellular tissue engineered vessel (ATEV) for vascular trauma, was approved by the FDA in December 2024. Other ATEV applications remain in late-stage trials or preclinical development and, except for extremity vascular trauma, are investigational.
Humacyte (Nasdaq: HUMA) announced that the U.S. FDA has accepted its Investigational New Drug (IND) application for a first-in-human clinical study of its coronary tissue engineered vessel (CTEV) for use in coronary artery bypass grafting (CABG). According to Humacyte, a Phase 2a trial in CABG patients is expected to begin during the current quarter and will enroll ten adult patients. The study will evaluate safety and efficacy, with a primary assessment of CTEV patency (blood flow) at two months and patient follow-up for up to three years.
The CTEV is described as a first-in-class, universally implantable bioengineered human blood vessel, manufactured using the same system as Humacyte’s FDA-approved acellular tissue engineered vessel (ATEV) for extremity vascular trauma. Preclinical CABG models in pigs, sheep and baboons reportedly supported IND clearance. In a six-month baboon study published in JACC: Basic to Translational Science, the CTEV was observed to maintain patency, recellularize with host vascular cells, and remodel to reduce size mismatch with native coronary arteries. Humacyte notes that CTEV and non-trauma indications for ATEV remain investigational and are not approved for sale.
Humacyte (Nasdaq: HUMA) announced that leading nephrologists Robert J. Kossmann, MD, and Prabir Roy-Chaudhury, MD, PhD, have joined as advisors to support planned commercialization of Humacyte’s acellular tissue engineered vessel (ATEV) for hemodialysis access.
According to Humacyte, the advisors will help shape health economic, reimbursement and market access strategies and provide peer-to-peer scientific and medical education. The appointments follow positive results from the V012 Phase 3 dialysis access study in women and the company’s plan to file a supplemental Biologic License Application with the FDA. Outside its FDA-approved extremity vascular trauma indication, the ATEV remains investigational and is not approved for sale by any regulatory agency.
Humacyte (Nasdaq:HUMA) reported positive Phase 3 V012 results for its bioengineered blood vessel (ATEV) in women on dialysis. ATEV patients averaged 220 catheter-free days in year one vs 129 with AV fistula, and had fewer infections.
The study met its primary superiority endpoint, leading to enrollment termination per protocol. Safety profiles were comparable. Humacyte plans to file a supplemental BLA with the FDA in the second half of 2026, targeting adults with end-stage kidney disease at high risk of AV fistula maturation failure.
Humacyte (Nasdaq:HUMA) priced an underwritten public offering of 47,619,048 shares of common stock at $1.05 per share, targeting approximately $50 million in gross proceeds. Closing is expected around June 12, 2026, with a 30-day option for underwriters to buy up to 7,142,857 additional shares.
All shares are offered by Humacyte. Net proceeds are earmarked to commercialize Symvess, support a planned BLA supplement for a hemodialysis indication, advance pipeline candidates, and for working capital and general corporate purposes. Barclays, BTIG and Titan Partners act as joint book-running managers.
Humacyte (Nasdaq:HUMA) has launched an underwritten public offering of common stock, with all shares sold by the company and a 30-day option for underwriters to buy up to 15% additional shares. Proceeds are expected to fund Symvess commercialization, a planned hemodialysis BLA supplement, pipeline development, and general corporate purposes.
Humacyte (Nasdaq:HUMA) reported positive interim Phase 3 V012 results for its acellular tissue engineered vessel (ATEV) in female dialysis access patients.
The ATEV met the primary endpoint, delivering an average of 220 catheter-free days vs 129 for autologous AV fistula (difference 91 days, p=0.00070). Infection rates were 6 vs 23 per 100 patient years, with no access-associated infections in ATEV patients. Enrollment will stop at 120 patients, and Humacyte plans a supplemental BLA filing with the FDA in 2H 2026 for adult end-stage kidney disease patients at increased risk of AV fistula maturation failure.